Aduro Biotech Inc

Aduro Biotech — Jefferies Virtual Healthcare Conference 2020

18 slides from Aduro Biotech's conference presentation, Jun 2, 2020

  1. Slide 1: Chinook Therapeutics: Developing Precision Medicines for Kidney Diseases

    Slide 1: Chinook Therapeutics: Developing Precision Medicines for Kidney Diseases

    Chinook Therapeutics Developing Precision Medicines for Kidney Diseases Jefferies Virtual Healthcare Conference June 3, 2020

  2. Slide 2: Note Regarding Forward-Looking Statements

    Slide 2: Note Regarding Forward-Looking Statements

    Note Regarding Forward-Looking Statements This presentation contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “may,” “will,” “contin

  3. Slide 3: Proposed Merger with Aduro Biotech

    Slide 3: Proposed Merger with Aduro Biotech

    Proposed Merger with Aduro Biotech Chinook and Aduro Biotech have agreed to a proposed ~50:50 merger Expected to provide strong financial position with ~$200M in cash, cash equivalents and marketable securities expected at closing Includes $25M in additional investment committed by Chinook’s existin

  4. Slide 4: The Time is Now for Kidney Disease Drug Development

    Slide 4: The Time is Now for Kidney Disease Drug Development

    The Time is Now for Kidney Disease Drug Development Emerging patient stratification approaches and translational platforms Causal mutations, biomarkers, single-cell sequencing, organoid / podocyte systems Underserved market with >$100B of annual healthcare costs in U.S. Few new drugs approved in pas

  5. Slide 5: Developing Precision Medicines for Kidney Disease

    Slide 5: Developing Precision Medicines for Kidney Disease

    Developing Precision Medicines for Kidney Disease Chinook’s pipeline is driven by deep insights into disease biology and focused on indications with validated pathways and rapid development opportunities Atrasentan: Phase 3 asset in glomerular diseases Recently in-licensed from AbbVie Well-character

  6. Slide 6: Building a Robust, Diversified Pipeline

    Slide 6: Building a Robust, Diversified Pipeline

    Building a Robust, Diversified Pipeline Program Indication Target Validation Lead Optimization IND-Enabling Phase 1 Phase 2 Phase 3 Atrasentan IgA Nephropathy (IgAN) Basket of glomerular diseases CHK-336 Ultra-rare kidney disease Research Programs Other rare, severe chronic kidney diseases including

  7. Slide 7: Experienced Leadership Team

    Slide 7: Experienced Leadership Team

    Experienced Leadership Team ~35 FTEs including leaders in chemistry, biology, DMPK, translational medicine, clinical development, regulatory, CMC and G&A Executive Team Current Board Jerel Davis, PhD Paul Eisenberg, MD Srini Akkaraju, MD, PhD Jeremy Caldwell, PhD Eric Dobmeier Preston Klassen, MD, M

  8. Slide 8: Long-Term Vision: Building the Leading Company Developing Precision Medicines for Renal Disease

    Slide 8: Long-Term Vision: Building the Leading Company Developing Precision Medicines for Renal Disease

    Long-Term Vision: Building the Leading Company Developing Precision Medicines for Renal Disease Guiding R&D Principles: Focus on key pathways in kidney disease Design novel, target and differentiated molecules Utilize new and efficient translational approaches to speed R&D Execute clinical trials in

  9. Slide 9: Atrasentan

    Slide 9: Atrasentan

    Atrasentan Potent and Selective Endothelin A Receptor Antagonist for the Potential Treatment of IgA Nephropathy (IgAN) and Other Primary Glomerular Nephropathies (GNs)

  10. Slide 10: Atrasentan

    Slide 10: Atrasentan

    Atrasentan Atrasentan is an investigational, potent, selective endothelin A (ETA) receptor antagonist previously developed by AbbVie Extensively studied with clinical data in >5,000 diabetic kidney disease patients Reduced proteinuria and preserved kidney function in clinical trials Well-characteriz

  11. Slide 11: Atrasentan: Potent, Highly-Selective ETA Inhibitor with Established Renal Protection

    Slide 11: Atrasentan: Potent, Highly-Selective ETA Inhibitor with Established Renal Protection

    Studied in >5,000 diabetic kidney disease (DKD) patients, including global SONAR Phase 3 study Atrasentan is an Investigational Potent, Highly-Selective ETA Inhibitor with Clinically Established Renal Protection in CKD Proteinuria Rapid and sustained reductions in proteinuria consistently observed W

  12. Slide 12: Global SONAR Phase 3 Outcome Trial in DKD

    Slide 12: Global SONAR Phase 3 Outcome Trial in DKD

    Global SONAR Phase 3 Outcome Trial in DKD *Responders classified as patients who achieved >30% reduction in proteinuria “These data support a potential role for selective endothelin receptor antagonists in protecting renal function in patients with type 2 diabetes at high risk of developing end-stag

  13. Slide 13: SONAR Outcomes Supportive of Evaluation in IgA Nephropathy

    Slide 13: SONAR Outcomes Supportive of Evaluation in IgA Nephropathy

    Proteinuria (UACR)* Kidney Function (eGFR Slope)* Proteinuria reduction at 6-9 months expected to be potential endpoint to seek accelerated approval in IgAN eGFR slope is potential confirmatory efficacy endpoint to seek full approval in IgAN Treatment effects on proteinuria predict stronger effects

  14. Slide 14: IgA Nephropathy

    Slide 14: IgA Nephropathy

    IgA Nephropathy A progressive, chronic glomerular disease with limited treatment options Wyatt, R. J., & Julian, B. A. (2013). IgA nephropathy. New England Journal of Medicine, 368(25), 2402-2414. (https://doi.org/10.1056/NEJMra1206793) Strategy to target key molecular drivers of progressive IgA Nep

  15. Slide 15: Why Chinook?

    Slide 15: Why Chinook?

    Why Chinook? Kidney disease is a large underserved market poised to be transformed by recent advances in the understanding of underlying diseases and new approaches to drug development Unique late-stage opportunity with lead asset atrasentan Building a differentiated and proprietary pipeline targeti

  16. Slide 16: Important Additional Information and Where to Find It

    Slide 16: Important Additional Information and Where to Find It

    Important Additional Information and Where to Find It This communication contains information in respect of the proposed merger involving Aduro Biotech, Inc. and Chinook Therapeutics U.S., Inc. Aduro plans to file with the Securities and Exchange Commission (the “SEC”) a current report on Form 8-K,

  17. Slide 17: Participants in the Solicitation

    Slide 17: Participants in the Solicitation

    Participants in the Solicitation This communication does not constitute a solicitation of proxy, an offer to purchase or a solicitation of an offer to sell any securities. Aduro and Chinook, and each of their respective directors, executive officers and certain employees may be deemed to be particip

  18. Slide 18: Chinook Therapeutics: Developing Precision Medicines for Kidney Diseases

    Slide 18: Chinook Therapeutics: Developing Precision Medicines for Kidney Diseases

    Chinook Therapeutics Developing Precision Medicines for Kidney Diseases Jefferies Virtual Healthcare Conference June 3, 2020

Source: SEC EDGAR · 425 filed Jun 2, 2020

More decks from Aduro Biotech Inc